Navigation Links
Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
Date:5/19/2011

CARLSBAD, Calif., May 19, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 1 clinical study for ISIS-TTRRx.  ISIS-TTRRx is designed to treat transthyretin amyloidosis, a severe and rare genetic disease characterized by slow degeneration of peripheral nerve and/or heart tissues. ISIS-TTRRx is the first antisense drug to enter development under Isis' strategic alliance with GSK.

"We are very pleased with the successes of our collaboration with GSK, a partner with significant expertise in the development of drugs to treat severe and rare diseases.  In a little over a year, we have begun clinical development on the first drug in this collaboration, and we look forward to moving additional drugs from this collaboration into our pipeline," said B. Lynne Parshall, Chief Operating Officer and CFO of Isis.   "The progress we have made with GSK is representative of the value this type of alliance can provide to us and to our partners.  The innovative structure of this alliance allows us to control and facilitate rapid development of drugs while working together with a high-quality partner to maximize the value of the drugs in late-stage development and commercialization.  Already we have earned $48 million in payments from GSK, including $8 million this year.  This year, we anticipate making significant progress in our drugs to treat severe and rare diseases, such as transthyretin amyloidosis."

ISIS-TTRRx is an antisense drug that targets transthyretin, or TTR, for the treatment of transthyretin amyloidosis, a fatal disease that affects one in 100,000 people or about 50,000 people worldwide.  ISIS-TTRRx will initially be developed for patients with familial amyloid polyneuropathy, or FAP, who hav
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
4. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
7. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
8. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
9. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
10. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
11. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Fla. , Aug. 26, 2014 ... under the symbol (NUUU) has two (2) wholly- ... Our two subsidiaries harness scientifically advanced technology to ... NUUU,s Renuell Int,l, Inc. is ... anti-aging skin care products that is made possible ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
(Date:8/26/2014)... -- Albany Molecular Research Inc. (NASDAQ: AMRI ... President and Chief Executive Officer at AMRI, will present ... September 8, 2014 at 8:45 a.m. ET. ... be accessed at AMRI,s Investor Relations web site at ... archived for 90 days following the live presentation. ...
(Date:8/26/2014)... Historically, drug development has faced a ... grow – high attrition rate, low productivity, patent ... regulatory hurdles and increasing concern about adverse ... the traditional business model of pharmaceutical companies is ... to find better ways to reduce operational costs ...
Breaking Biology Technology:Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4Transitioning from Bench into Clinical Phase, new webinar hosted by Xtalks 2
... - Educators and software developers will have the ... learning process at the first annual Games+Learning+Society conference ... conference is being held by Games And Professional Practice ... Learning (ADL) Co-Lab and a group of instructors at ...
... Marquette University and UGS, a provider ... the largest in-kind contribution ever presented to Marquette University, in ... a market value it says is more than $30.5 million. ... Jim Factor's Geometric Modeling Lab in the Department of Mathematics, ...
... Assembly on Thursday passed AB 499, a proposed ban on ... would outlaw the cloning of embryos both for reproductive purposes ... the making of a cloned embryo for the purpose of ... were to become law would go up to ten years ...
Cached Biology Technology:Education conference to draw together games researchers 2
(Date:8/25/2014)... fires began as a lightning strike on August 12, 2014. ... 20% contained. There are close to 2,000 personnel ... many small fires and a number of large ones. ... account for about 100 acres. An inversion layer settled ... on August 24, keeping fire activity moderate. As the inversion ...
(Date:8/25/2014)... Many Americans need extraordinary willpower to avoid becoming obese ... too much. For members of minority groups, maintaining a ... new research led by Luis Rivera, an experimental social ... common for minorities in the United States to endure ... inferior, and that these attitudes can prevent people from ...
(Date:8/25/2014)... 2014 Nearly 1 in 6 adults worldwide may ... disorder can cause serious complications. Auriculotherapy, a form ... the outer ear, may help in managing constipation. ... that evaluated the effectiveness of auriculotherapy in treating ... a Review article in The Journal of ...
Breaking Biology News(10 mins):Happy Camper and July Fire Complexes in California 2Racial and ethnic stereotypes may contribute to obesity among minorities 2
... its damaging effect on the environment and its illegal ... to adverse effects on human health, such as inflammation ... damage and possibly cancer. In a ... journal Environmental Research Letters, researchers took air ...
... pinpoint a small RNA that spurs cells to manufacture a ... Alzheimer,s disease (AD) or other types of neurodegeneration. The study ... of Cell Biology ( www.jcb.org ). Like ... in more than one version. Although scientists have identified numerous ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
Cached Biology News:'E-waste pollution' a threat to human health, new research suggests 2Novel pathway regulating angiogenesis may fight retinal disease, cancers 2
... rapid analytical to medium scale affinity purification ... vectors. Sufficient reagents are provided for purification ... under native or denaturing conditions. Crude samples ... retains STag fusion proteins. After unbound proteins ...
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, 5 ... 0.3 ,Ferric ammonium citrate, 0.5 ,IPTG, ... water soluble, autoclavable chromogenic substrate for ... by -galactosidase generates a black insoluble ...
S-100 alpha/beta chain (8B10)...
Biology Products: